Clinical Trial Search

Primary: Accuracy Evaluation: The Degree of Agreement (%) of the ACR | U.S. Urine Analysis Test System as Compared to the Comparator Device — 506; 546; 497; 546 Tests

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 6; 4 Participants

Primary: Number of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent…

Primary: Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles — 3.7 score on a scale

Primary: Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS) — -49.5; -71.3; -29.9 percentage change

Primary: Rapid Visual Information Processing (RVP) Sensitivity [A'] — 0.94; 0.93; 0.95; 0.96 probability of detecting sequence — p=<0.001

Primary: Risk for Gastrointestinal (GI) and Genitourinary (GU) Toxicity — 0; 0; 1.8; 0.7 percentage of participants

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Islet Graft Function — 233; 354 ng/ml*min

Primary: Change in Mean Length of Utterance (MLU) — 0.5387; 0.2987 Morphemes per utterance — p=<0.555

Primary: Part A: Number of Participants With All Non-serious Adverse Events (AEs) and Serious AEs (SAEs) Following Administration of Oral Dose — 1; 2; 3; 1 Participants

Primary: Ease of Lens Insertion — 92.1; 90.9 units on a scale

Primary: Number of Participants With Complete Response — 13; 21; 33; 24 Participants

Primary: Serum Etonogestrel Concentrations — 164.0; 47.8 pg/mL

Primary: Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations — 0; 0; 0; 0 events